Widely used:Recently Viewed
Clear All
Today’s Range
52 Week Range
Liquidity
Market cap
$9,827 Mln
P/E Ratio
63.43
P/B Ratio
4.73
Industry P/E
--
Debt to Equity
0.14
ROE
0.08 %
ROCE
6.85 %
Div. Yield
0.51 %
Book Value
--
EPS
0.98
CFO
$2,052.47 Mln
EBITDA
$2,284.27 Mln
Net Profit
$1,548.89 Mln
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|
|---|---|---|---|---|---|---|---|
|
Bio-Techne Corp (TECH)
| -13.12 | -5.10 | -17.83 | -13.71 | 111.49 | 90.14 | 45.00 |
|
BSE Sensex*
| -3.91 | -1.06 | -6.81 | 3.51 | 9.12 | 19.71 | 10.10 |
|
S&P Small-Cap 600#
| -5.82 | -5.34 | -13.73 | -6.30 | 5.30 | 2.98 | 5.53 |
|
2024
|
2023
|
2022
|
2021
|
2020
|
2019
|
2018
|
|
|---|---|---|---|---|---|---|---|
|
Bio-Techne Corp (TECH)
| -6.60 | -6.90 | 925.31 | 62.92 | 44.66 | 51.68 | 11.64 |
|
S&P Small-Cap 600
| 7.01 | 13.89 | -17.42 | 25.27 | 9.57 | 20.86 | -9.70 |
|
BSE Sensex
| 8.10 | 18.74 | 4.44 | 21.99 | 15.75 | 14.38 | 5.87 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
3Y Avg -- 5Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price ($) | Market Cap ($ Mln) | P/E Ratio | ROE |
|---|---|---|---|---|
| 37.02 | 10,257.64 | 20.82 | 23.13 | |
| 34.71 | 13,384.89 | -- | -28.77 | |
| 111.50 | 11,042.16 | 33.66 | 14.16 | |
| 101.35 | 9,430.55 | 41.53 | 19.71 |
Bio-Techne Corporation, together with its subsidiaries, develops, manufactures, and sells life science reagents, instruments, and services for the research, diagnostics, and bioprocessing markets worldwide. The company operates through two segments,... Protein Sciences, and Diagnostics and Genomics. The Protein Sciences segment develops and manufactures biological reagents used in various aspects of life science research, diagnostics, and cell and gene therapy, such as cytokines and growth factors, antibodies, small molecules, tissue culture sera, and cell selection technologies. This segment also offers proteomic analytical tools for automated western blot and multiplexed ELISA workflow consists of manual and automated protein analysis instruments and immunoassays for use in quantifying proteins in various biological fluids. The Diagnostics and Genomics segment develops and manufactures diagnostic products, including controls, calibrators, and diagnostic assays for regulated diagnostics market, exosome-based molecular diagnostic assays, advanced tissue-based in-situ hybridization assays for spatial genomic and tissue biopsy analysis, and genetic and oncology kits for research and clinical applications; and sells products for genetic carrier screening, oncology diagnostics, molecular controls, and research, as well as instruments and process control products for hematology, blood chemistry and gases, and coagulation controls and reagents used in various diagnostic applications. The company has strategic partnership with ALZpath, Inc. to accelerate breakthroughs in neurodegenerative disease research and treatment, including Alzheimer's disease. The company was formerly known as Techne Corporation and changed its name to Bio-Techne Corporation in November 2014. Bio-Techne Corporation was incorporated in 1976 and is headquartered in Minneapolis, Minnesota. Address: 614 McKinley Place N.E., Minneapolis, MN, United States, 55413 Read more
CEO, President & Director
Mr. Kim Kelderman
CEO, President & Director
Mr. Kim Kelderman
Headquarters
Minneapolis, MN
Website
Our rating system has guided millions of investors in the past 20 years.
The total asset value of Bio-Techne Corp (TECH) stood at $ 2,832 Mln as on 31-Dec-24
The share price of Bio-Techne Corp (TECH) is $62.58 (NASDAQ) as of 17-Mar-2025 16:00 EDT. Bio-Techne Corp (TECH) has given a return of 111.49% in the last 3 years.
Bio-Techne Corp (TECH) has a market capitalisation of $ 9,827 Mln as on 17-Mar-2025. As per Value Research classification, it is a Small Cap company.
The P/B ratio of Bio-Techne Corp (TECH) is 4.73 times as on 17-Mar-2025, a 75% premium to its peers’ median range of 2.71 times.
The P/E ratio of Bio-Techne Corp (TECH) is 63.43 times as on 17-Mar-2025.
Step 1. Open a demat account through a broker. You would need to provide your email, PAN, bank account details, aadhar details, etc., for KYC
Step 2. Sign in to the broker’s application through a mobile app or website. Use the Login ID and password provided by your broker.
Step 3. Transfer funds from your bank account into the wallet present in your brokerage account.
Step 4. Search for the Bio-Techne Corp (TECH) and enter the required number of quantities and click on buy to purchase the shares of Bio-Techne Corp (TECH).
Bio-Techne Corporation, together with its subsidiaries, develops, manufactures, and sells life science reagents, instruments, and services for the research, diagnostics, and bioprocessing markets worldwide. The company operates through two segments, Protein Sciences, and Diagnostics and Genomics. The Protein Sciences segment develops and manufactures biological reagents used in various aspects of life science research, diagnostics, and cell and gene therapy, such as cytokines and growth factors, antibodies, small molecules, tissue culture sera, and cell selection technologies. This segment also offers proteomic analytical tools for automated western blot and multiplexed ELISA workflow consists of manual and automated protein analysis instruments and immunoassays for use in quantifying proteins in various biological fluids. The Diagnostics and Genomics segment develops and manufactures diagnostic products, including controls, calibrators, and diagnostic assays for regulated diagnostics market, exosome-based molecular diagnostic assays, advanced tissue-based in-situ hybridization assays for spatial genomic and tissue biopsy analysis, and genetic and oncology kits for research and clinical applications; and sells products for genetic carrier screening, oncology diagnostics, molecular controls, and research, as well as instruments and process control products for hematology, blood chemistry and gases, and coagulation controls and reagents used in various diagnostic applications. The company has strategic partnership with ALZpath, Inc. to accelerate breakthroughs in neurodegenerative disease research and treatment, including Alzheimer's disease. The company was formerly known as Techne Corporation and changed its name to Bio-Techne Corporation in November 2014. Bio-Techne Corporation was incorporated in 1976 and is headquartered in Minneapolis, Minnesota. Address: 614 McKinley Place N.E., Minneapolis, MN, United States, 55413
The CEO & director of Mr. Kim Kelderman. is Bio-Techne Corp (TECH), and CFO & Sr. VP is Mr. Kim Kelderman.
There is no promoter pledging in Bio-Techne Corp (TECH).
Some of the close peers are:
| Company | Market Cap($ Mln) |
|---|---|
|
1,168
|
|
|
1,141
|
|
|
1,072
|
|
|
1,045
|
| Bio-Techne Corp (TECH) | Ratios |
|---|---|
|
Return on equity(%)
|
7.61
|
|
Operating margin(%)
|
19.35
|
|
Net Margin(%)
|
13.22
|
|
Dividend yield(%)
|
--
|
No, TTM profit after tax of Bio-Techne Corp (TECH) was $0 Mln.
$0.42
(
